Cytoprotective effect of silybin against lasalocid-induced toxicity in HepG2 cells

• Autorzy: Radko L. , Cybulski W. , Rzeski W.
• Języki publikacji: EN

Abstrakty

EN

Lasalocid is an ionophore coccidiostatic agent frequently used in poultry. Its extensive use causes the formation of residues in edible tissues and eggs which may pose a risk to consumers. Silybin is the main compound extracted from the herb milk thistle Silybum marianum and its hepatoprotective effect has been reported in literature. The aim of the study was to compare lasalocid and silybin cytotoxic effects followed by their combined use in HepG2 cell line. A cytoprotective effect resulting from the interaction of both pharmacologically active substances was measured. In this study, an MTT test, coomassie brillant blue binding test, and LDH release test determined the effective concentration (EC₅₀) of the compounds. The isobolograms and combination index were used to assess the nature of interaction. The lowest EC₅₀-value for lasalocid was established via the MTT test. This study revealed a lack of silybin cytotoxic effect on the cells. Co-actions of the two drugs led to a significant decrease of lasalocid cytotoxicity. The isobolograms and combination index showed a remarkable antagonistic effect in the course of silybin and lasalocid interaction. The results indicate that silybin revealed a cytoprotective effect when incubated with lasalocid since its cytotoxic impact on HepG2 cells has been significantly diminished.

• Wydawca: -
• Czasopismo: Polish Journal of Veterinary Sciences
• Rocznik: 2013
• Tom: 16
• Numer: 2
• Opis fizyczny: p.275-282,fig.,ref.

Twórcy

autor

Radko L.

• Department of Pharmacology and Toxicology National Veterinary Research Institute, Partyzantow 57, 24-100 Pulawy, Poland

autor

Cybulski W.

• Department of Virology and Immunology, Institute of Microbiology and Biotechnology, Maria Curie-Sklodowska University, Akademicka 19, 20-033 Lublin, Poland

autor

Rzeski W.

• Department of Virology and Immunology, Institute of Microbiology and Biotechnology, Maria Curie-Sklodowska University, Akademicka 19, 20-033 Lublin, Poland

Bibliografia

• Angeli JP, Barcelos GR, Serpeloni JM, Barbosa FJr, Nersesyan A, Mantovani MS (2010) Evaluation of the genotoxic and anti-genotoxic activities of silybin in human hepatoma cells (HepG2). Mutagenesis 25: 223-229.
• Anon (1992) The ERGATT/FRAME data bank of in vitro techniques in toxicology. The frame cytotoxicity test (kenacid blue). INVITTOX protocol No. 3b. Nottingham UK. INVITTOX.
• Antonio RV, Silva LP, Vercesi AE (1991) Alterations in mitochondrial Ca²⁺ flux by the antibiotic X-537A (lasalocid-A). Biochim Biophys Acta 1056: 250-258.
• Avizeh R, Najafzadeh H, Razijalali M, Shirali S (2009) Evaluation of prophylactic and therapeutic effects of silymarin and N-acetylcysteine in acetaminophen-induced hepatotoxicity in cats. J Vet Pharmacol Ther 33: 95-99.
• Bolkent S, Zierold K (2002) Effects of the ionophores valinomycin, ionomycin and gramicidin A on the element compartmentation in cultured rat hepatocytes. Toxicol In Vitro 16: 159-165.
• Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
• Chen CH, Huang TS, Wong CH, Hong CL, Tsai YH, Liang CC, Lu FJ, Chang WH (2009) Synergistic anti-cancer effect of baicalein and silymarin on human hepatoma HepG2 cells. Food Chem Toxicol 47: 638-644.
• Chou TC, Talalay P (1983) Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4: 450-454.
• Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
• Clothier R, Dierickx P, Lakhanisky T, Fabre M, Betanzos M, Curren R, Sjostrom M, Raabe H, Bourne N, Hernandez V, Mainez J, Owen M, Watts S, Anthonisen R (2008) A database of IC50 values and principal component analysis of results from six basal Cytotoxicity assays, for use in the modeling of the in vivo and in vitro data of the EU AcuteTox project. Alternatives to Laboratory Animals 36: 503-519.
• Dvorak Z, Kosina P, Walterova D, Simhnek V, Bachleda P, Ulrichovh J (2003) Primary cultures of human hepatocytes as a tool in cytotoxicity studies: cell protection against model toxins by flavonolignans obtained from Silybum marianum. Toxicol Lett 137: 201-212.
• Dvorak Z, Vrzal R, Ulrichova J (2006) Silybin and dehydrosilybin inhibit cytochrome P450 1 A1 catalytic activity: a study in human keratinocytes and human hepatoma cells. Cell Biol Toxicol 22: 81-90.
• Fraschini F, Demartini G, Esposti D (2002) Pharmacology of silymarin. Clin Drug Invest 22: 51-65.
• Gazak R, Walterova D, Kren V (2007) Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem 14: 315-338.
• Gessner PK (1995) Isobolographic analysis of interactions: an update on applications and utility. Toxicology 105: 161-179.
• Grijalba MT, Andrade PB, Meinicke AR, Castilho RF, Vercesi AE, Schreier S (1998) Inhibition of membrane lipid peroxidation by a radical scavenging mechanism: a novel function for hydroxyl-containing ionophores. Free Radic Res 28: 301-318.
• Grinde B (1983) Effect of carboxylic ionophores on lysosomal protein degradation in rat hepatocytes. Exp Cell Res 149: 27-35.
• Kouyoumdjian JA, Morita MP, Sato AK, Pissolatti AF (2001) Fatal rhabdomyolysis after acute sodium monensin (Rumensin®) toxicity: case report. Arq Neuro-Psiquiatr 59:3A S4o Paulo Sept.
• Kowaltowski AJ, Vercesi AE (1999) Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med 26: 463-471.
• Kren V, Walterova D (2005) Silybin and silymarin – new effects and applications. Biomed Pap Med Fac Univ Palacky Olomouc 149: 29-41.
• Lah JJ, Cui W, Hu KQ (2007) Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol 13: 5299-5305.
• Loranger A, Gicquaud C, Tuchweber B (1982) Effect of silybin on phalloidin-actin interactions in vitro. Toxicol Lett 11: 111-117.
• Mehrotra S, Viswanathan PN, Kakkar P (1993) Influence of some biological response modifiers on swelling of rat liver mitochondria in vitro. Mol Cell Biochem 124: 101-106.
• Mortier L, Huet AC, Charlier C, Daeseleire E, Delahaut P, van Peteghem C (2005) Incidence of residues of nine anticoccidials in eggs. Food Addit Contam 22: 1120-1125.
• Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
• Oh H, Kim DH, Cho JH, Kim YC (2004) Hepatoprotective and free radical scavenging activities of phenolic petrosins and flavonoids isolated from Equisetum arvense. J Ethnopharmacol 95: 421-424.
• Olejnik M, Szprengier-Juszkiewicz T (2007) Coccidiostats residues in poultry tissues and eggs. Med Weter 63: 1539-1545.
• Ponsoda X, Jover R, Núnez C, Royo M, Castell JV, Gómez-Lechón MJ (1995) Evaluation of the cytotoxicity of 10 chemicals in human and rat hepatocytes and in cell lines: correlation between in vitro data and human lethal concentration. Toxicol In Vitro 9: 959-966.
• Pook SH, Toh CK, Mahendran R (2006) Combination of thiol antioxidant Silibinin with Brostallicin is associated with increase in the anti-apoptotic protein Bcl-2 and decrease in caspase 3 activity. Cancer Lett 238: 146-152.
• Radko L, Cybulski W, Rzeski W (2007) Cytotoxicity of salinomycin and lasalocid in a model hepatocyte cell line of a rat. Med Weter 63: 839-842.
• Radko L, Cybulski W, Rzeski W (2011) Cytotoxicity studies of lasalocid and silibinin in rat hepatoma cell culture. Bull Vet Inst Pulawy 55: 547-554.
• Ramadan LA, Roushdy HM, Abu Senna GM, Amin NE, El-Deshw OA (2002) Radioprotective effect of silymarin against radiation induced hepatotoxicity. Pharmacol Res 45: 447-454.
• Safran N, Aizenberg I, Bark H (1993) Paralytic syndrome attributed to lasalocid residues in a commercial ration fed to dogs. J Am Vet Med Assoc 202: 1273-1275.
• Sasaki T, Kawai K, Saijo-Kurita K, Ohno T (1992) Detergent cytotoxicity: simplified assay of cytolysis by measuring LDH activity. Toxicol In Vitro 6: 451-457.
• Sherlock S, Dooley J (2002) Diseases of liver and biliary system. 11th ed., Oxford: Blackwell Scientific Publications.
• Thabrew MI, Hughes RD, McFarlane IG (1997) Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay. J Pharm Pharmacol 49: 1132-1135.
• Tyagi AK, Agarwal C, Chan DC, Agarwal R (2004) Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep 11: 493-499.
• Varghese L, Agarwal C, Tyagi A, Singh RP, Agarwal R (2005) Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res 11: 8441-8448.
• Wellington K, Jarvis B (2001) Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15: 465-489.
• Wesołowska O, Łania-Pietrzak B, Kuzdzał M, Stanczak K, Mosiadz D, Dobryszycki P, Ozyhar A, Komorowska M, Hendrich AB, Michalak K (2007) Influence of silybin on biophysical properties of phospholipid bilayers. Acta Pharmacol Sin 28: 296-306.
• Wong RY, Roxburgh JW (2010) Lasalocid awareness and sampling in Scotland. Int J Environ Health Res 20: 159-169.